glp-1 masld Two Pediatric Publications: Call for Action and Use of RAs GLP-1s are gaining traction in

Dosing in the Phase 3 Diabetes Trial (TRANSCEND-T2D-1) A1C reduction: -1.7% to -2.0% across doses (from baseline 7-9.5%) Weight loss at 12 mg: 16.8% (-36.6 lbs) at 40 weeks Discontinuation due to adverse events was relatively low across all doses, similar to the patterns seen in TRIUMPH-4 The diabetes population typically loses less weight on GLP-1 drugs than the obesity-only population, which is consistent with what was observed: ~17% weight loss in T2D vs

The powder inside that vial is delicate

They are one part of a holistic approach to safe, sustainable weight loss

Side effect tolerance plays a role

we ensure our clients achieve healthy, sustainable results by using advanced tools to track fat loss and preserve muscle

Dehydration and kidney injury Repeated vomiting or diarrhea can cause volume depletion